Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Director Patrick G. Enright sold 9,000 shares of the company’s stock in a transaction on Monday, December 11th. The stock was sold at an average price of $139.73, for a total value of $1,257,570.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Shares of Jazz Pharmaceuticals PLC (NASDAQ JAZZ) opened at $135.50 on Friday. The firm has a market capitalization of $8,430.84, a PE ratio of 17.65, a price-to-earnings-growth ratio of 0.91 and a beta of 0.98. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.94 and a current ratio of 3.10. Jazz Pharmaceuticals PLC has a 12-month low of $102.65 and a 12-month high of $163.75.

A number of equities analysts have recently issued reports on JAZZ shares. HC Wainwright started coverage on Jazz Pharmaceuticals in a research report on Friday, August 25th. They set a “neutral” rating and a $144.00 price target on the stock. Cantor Fitzgerald reissued a “buy” rating and issued a $200.00 target price on shares of Jazz Pharmaceuticals in a research report on Sunday, December 3rd. FBR & Co started coverage on Jazz Pharmaceuticals in a research report on Thursday, October 19th. They issued a “buy” rating and a $206.00 target price on the stock. Morgan Stanley started coverage on Jazz Pharmaceuticals in a research report on Thursday, October 5th. They issued an “equal weight” rating and a $155.00 target price on the stock. Finally, Zacks Investment Research downgraded Jazz Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, October 31st. Two analysts have rated the stock with a sell rating, five have issued a hold rating and nineteen have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $181.28.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. AXA grew its position in Jazz Pharmaceuticals by 23.2% during the 3rd quarter. AXA now owns 116,862 shares of the specialty pharmaceutical company’s stock worth $17,091,000 after purchasing an additional 22,007 shares during the period. Neuberger Berman Group LLC grew its position in Jazz Pharmaceuticals by 26.6% during the 3rd quarter. Neuberger Berman Group LLC now owns 117,345 shares of the specialty pharmaceutical company’s stock worth $17,162,000 after purchasing an additional 24,626 shares during the period. California Public Employees Retirement System grew its position in Jazz Pharmaceuticals by 4.8% during the 3rd quarter. California Public Employees Retirement System now owns 122,201 shares of the specialty pharmaceutical company’s stock worth $17,872,000 after purchasing an additional 5,601 shares during the period. Virtu Financial LLC acquired a new stake in Jazz Pharmaceuticals during the 3rd quarter worth about $291,000. Finally, Janney Montgomery Scott LLC grew its position in Jazz Pharmaceuticals by 29.4% during the 3rd quarter. Janney Montgomery Scott LLC now owns 1,760 shares of the specialty pharmaceutical company’s stock worth $257,000 after purchasing an additional 400 shares during the period. 91.30% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This report was published by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another site, it was copied illegally and reposted in violation of United States & international copyright law. The correct version of this report can be viewed at https://www.watchlistnews.com/patrick-g-enright-sells-9000-shares-of-jazz-pharmaceuticals-plc-jazz-stock/1765066.html.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Insider Buying and Selling by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.